Medtronic launches clinical trial of AdaptivCRT physiologic pacing algorithm

Medtronic ($MDT) announced an international clinical trial comparing standard cardiac resynchronization therapy against CRT with the AdaptivCRT physiologic pacing algorithm that makes automatic adjustments to the therapy. The 3,000-patient trial is intended to monitor and gather information on AdaptivCRT to see if the device increases the effectiveness of medical device intervention in heart failure patients. Patients were enrolled in 200 centers throughout five continents. All patients will be followed up at regularly scheduled intervals of three to 6 months to see if their condition is worsening and if they have any incidences of atrial fibrillation. The trial will also gather information about the subjects' overall quality of life with the device, as well as its cost-effectiveness. Release

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.